FIST, a sword and shield fusokine for cancer immunotherapy.

abstract：:Inflammatory chemokines are critical contributors in attracting relevant immune cells to the tumor microenvironment and driving cellular interactions and molecular signaling cascades that dictate the ultimate outcome of host anti-tumor immune response. Therefore, rational application of chemokines in a spatial-tempora...

journal_title：Oncoimmunology

authors： Allen F,Bobanga ID,Rauhe P,Barkauskas D,Teich N,Tong C,Myers J,Huang AY

更新日期：2017-11-20 00:00:00

abstract：:A Phase I trial of a p53-targeting modified vaccinia Ankara (p53MVA) vaccine in patients afflicted with refractory gastrointestinal cancers demonstrated enhanced T-cell recognition of p53 following vaccination. However, this effect was transient suggesting that p53MVA requires combination with immunomodulatory agents ...

journal_title：Oncoimmunology

authors： Hardwick N,Chung V,Cristea M,Ellenhorn JD,Diamond DJ

更新日期：2014-12-15 00:00:00

abstract：:The functional status of CD4(+) T cells is a critical determinant of antitumor immunity. Polyfunctional CD4(+) T cells possess the ability to concomitantly produce multiple Th1-type cytokines, exhibiting a functional attribute desirable for cancer immunotherapy. However, the mechanisms by which these cells are induced...

journal_title：Oncoimmunology

authors： Ding ZC,Liu C,Cao Y,Habtetsion T,Kuczma M,Pi W,Kong H,Cacan E,Greer SF,Cui Y,Blazar BR,Munn DH,Zhou G

更新日期：2016-04-25 00:00:00

abstract：:Regressing tumors are usually associated with a large immune infiltrate, but the molecular and cellular interactions that govern a successful anti-tumor immunity remain elusive. Here, we have triggered type I Interferon (IFN) signaling in a breast tumor model (MMTV-PyMT) using 5,6-dimethylxanthenone-4-acetic acid (DMX...

journal_title：Oncoimmunology

authors： Weiss JM,Guérin MV,Regnier F,Renault G,Galy-Fauroux I,Vimeux L,Feuillet V,Peranzoni E,Thoreau M,Trautmann A,Bercovici N

更新日期：2017-07-07 00:00:00

abstract：:The instauration of an immunosuppressive microenvironment is a key event in cancer development and progression. Here, we discuss increasing evidences of the crosstalk between myeloid-derived suppressor cells (MDSCs) and mast cells (MCs) as a new fuel for the cancer immunosuppressive machinery. ...

journal_title：Oncoimmunology

authors： Danelli L,Frossi B,Pucillo CE

更新日期：2015-03-24 00:00:00

abstract：:Cancer immunotherapy is hampered by the immunosuppression maintained by regulatory T cells (Tregs) in tumor-bearing hosts. Stimulation of the Toll-like receptor 2 (TLR2) by Pam3Cys is known to affect Treg-mediated suppression. We found that Pam3Cys increases the proliferation of both CD4(+) effector T cells (Teffs) an...

journal_title：Oncoimmunology

authors： Amiset L,Fend L,Gatard-Scheikl T,Rittner K,Duong V,Rooke R,Muller S,Bonnefoy JY,Préville X,Haegel H

更新日期：2012-11-01 00:00:00

abstract：:By analyzing CD4+ lymphocytes in human breast carcinomas, we have recently uncovered the presence of follicular helper T cells in lesions exhibiting an extensive immune infiltrate. The presence of these specialized CD4+ T cells, which localize to the germinal centers of peritumoral tertiary lymphoid structures found i...

journal_title：Oncoimmunology

authors： Gu-Trantien C,Willard-Gallo K

更新日期：2013-10-01 00:00:00

abstract：:Changes in the immune system induced by tyrosine kinase inhibitors (TKI) have been shown to positively correlate with therapy responses in chronic myeloid leukemia (CML). However, only a few longitudinal studies exist and no randomized comparisons between two TKIs have been reported. Therefore, we prospectively analyz...

journal_title：Oncoimmunology

authors： Kreutzman A,Yadav B,Brummendorf TH,Gjertsen BT,Hee Lee M,Janssen J,Kasanen T,Koskenvesa P,Lotfi K,Markevärn B,Olsson-Strömberg U,Stentoft J,Stenke L,Söderlund S,Udby L,Richter J,Hjorth-Hansen H,Mustjoki S

更新日期：2019-07-13 00:00:00

abstract：:Human papillomavirus (HPV) infection is one of the most important etiologic causes of oropharyngeal head and neck squamous cell carcinoma (HNSCC). Patients with HPV-positive HNSCC were reported to have a better clinical outcome than patients with HPV-negative cancers. However, little is known about the possible causes...

journal_title：Oncoimmunology

authors： Partlová S,Bouček J,Kloudová K,Lukešová E,Zábrodský M,Grega M,Fučíková J,Truxová I,Tachezy R,Špíšek R,Fialová A

更新日期：2015-01-30 00:00:00

abstract：:Graft-versus-host disease (GvHD) remains a significant impediment to allogeneic hematopoietic cell transplantation (HCT) success, necessitating studies focused on alleviating GvHD, while preserving the graft-versus-leukemia (GvL) effect. Based on our previous studies showing bendamustine with total body irradiation (B...

journal_title：Oncoimmunology

authors： Stokes J,Hoffman EA,Molina MS,Kummet N,Simpson RJ,Zeng Y,Katsanis E

更新日期：2020-04-30 00:00:00

abstract：:Natural killer (NK)-cell count is predictive of chronic lymphoid leukemia (CLL) disease progression and their dysfunction is well documented, but the etiology of this is currently lacking. CLL cells have been shown to over-express HLA-E, the natural ligand for NKG2A expressed on NK-cells that generates a distinct nega...

journal_title：Oncoimmunology

authors： McWilliams EM,Mele JM,Cheney C,Timmerman EA,Fiazuddin F,Strattan EJ,Mo X,Byrd JC,Muthusamy N,Awan FT

更新日期：2016-09-09 00:00:00

abstract：:Successful cancer immunotherapy is thought to require de novo priming of tumor specific CD8(+) T cells in lymphatic organs. Contrasting these beliefs, cancer therapy based on interleukin-10 (IL-10) results in tumor rejection without a requirement for T-cell trafficking from lymphatic organs. Rather, IL-10 directly act...

journal_title：Oncoimmunology

authors： Emmerich J,Mumm JB,Oft M

更新日期：2012-12-01 00:00:00

abstract：:Regulatory T cells (Tregs) facilitate primary and metastatic tumour growth through the suppression of anti-tumour immunity. Emerging evidence suggests a distinct role for Tregs in mediating tissue repair and barrier integrity in the lungs by IL-33 mediated production of the growth factor amphiregulin (AREG). Dependent...

journal_title：Oncoimmunology

authors： Halvorsen EC,Franks SE,Wadsworth BJ,Harbourne BT,Cederberg RA,Steer CA,Martinez-Gonzalez I,Calder J,Lockwood WW,Bennewith KL

更新日期：2018-10-16 00:00:00

abstract：:In many cancers, regulatory T cells (Treg) play a crucial role in suppressing the effector immune response thereby permitting tumor development. Indeed, in mouse models, their depletion can promote the regression of tumors of various origins, including renal cell carcinoma when located subcutaneous (SC). In the presen...

journal_title：Oncoimmunology

authors： Devaud C,Westwood JA,Teng MW,John LB,Yong CS,Duong CP,Smyth MJ,Darcy PK,Kershaw MH

更新日期：2014-12-21 00:00:00

abstract：:Tumor-infiltrating lymphocytes (TILs) are correlated to prognosis of several kinds of cancer. Most studies focused on T cells, while the role of tumor-associated B cells (TABs) has only recently gained more attention. TABs contain subpopulations with distinct functions, potentially promoting or inhibiting immune respo...

journal_title：Oncoimmunology

authors： Schlößer HA,Thelen M,Lechner A,Wennhold K,Garcia-Marquez MA,Rothschild SI,Staib E,Zander T,Beutner D,Gathof B,Gilles R,Cukuroglu E,Göke J,Shimabukuro-Vornhagen A,Drebber U,Quaas A,Bruns CJ,Hölscher AH,Von Bergwelt-Bai

更新日期：2018-11-02 00:00:00

abstract：:Chimeric antigen receptor (CAR) T cells have enjoyed unprecedented clinical success against haematological malignancies in recent years. However, several aspects of CAR T cell biology remain unknown. We recently compared CAR and T cell receptor (TCR)-based killing in the same effector cell and showed that CAR T cells ...

journal_title：Oncoimmunology

authors： Davenport AJ,Jenkins MR,Ritchie DS,Prince HM,Trapani JA,Kershaw MH,Darcy PK,Neeson PJ

更新日期：2015-06-01 00:00:00

abstract：:Ibrutinib, a BTK inhibitor, is currently used to treat various hematological malignancies. We evaluated whether ibrutinib treatment during development of murine bone marrow-derived dendritic cells (DCs) modulates their maturation and activation. Ibrutinib treatment increased the proportion of CD11c(+) DCs, upregulated...

journal_title：Oncoimmunology

authors： Natarajan G,Oghumu S,Terrazas C,Varikuti S,Byrd JC,Satoskar AR

更新日期：2016-03-10 00:00:00

abstract：:We have developed a highly versatile platform for the systematic retrieval of T-cell receptors (TCRs) from single-antigen-reactive T cells and for characterization of their function and specificity. This approach enables rapid extraction of multiple TCRs from repertoires in individuals and not only broadens the divers...

journal_title：Oncoimmunology

authors： Omokoko T,Simon P,Türeci Ö,Sahin U

更新日期：2015-03-19 00:00:00

abstract：:Recent data suggest that T-cell reactivity against tumor-specific neo-antigens may be central to the clinical efficacy of cancer immunotherapy. The development of personalized vaccines designed to boost T-cell reactivity against patient specific neo-antigens has been proposed largely on the basis of these findings. Wo...

journal_title：Oncoimmunology

authors： van Buuren MM,Calis JJ,Schumacher TN

更新日期：2014-05-14 00:00:00

abstract：:Interleukin (IL)-10 is a major cancer-related immunosuppressive factor, exhibiting a unique ability to hamper the maturation of dendritic cells (DCs). We have previously reported that IL-10 induces the conversion of activated, migratory CD1a+ DCs found in the human skin to CD14+CD141+ macrophage-like cells. Here, as a...

journal_title：Oncoimmunology

authors： Lindenberg JJ,van de Ven R,Lougheed SM,Zomer A,Santegoets SJ,Griffioen AW,Hooijberg E,van den Eertwegh AJ,Thijssen VL,Scheper RJ,Oosterhoff D,de Gruijl TD

更新日期：2013-04-01 00:00:00

abstract：:Objective:Ovarian cancer (OC) is often diagnosed at an advanced stage with two thirds of patients experiencing recurrent disease with a poor prognosis. Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) has shown curative potential in malignant melanoma, but has only been investigated scarcely in ot...

journal_title：Oncoimmunology

authors： Pedersen M,Westergaard MCW,Milne K,Nielsen M,Borch TH,Poulsen LG,Hendel HW,Kennedy M,Briggs G,Ledoux S,Nøttrup TJ,Andersen P,Hasselager T,Met Ö,Nelson BH,Donia M,Svane IM

更新日期：2018-09-26 00:00:00

abstract：:Despite increasing evidence for a protective role of invariant (i) NKT cells in the control of graft-versus-host disease (GVHD), the mechanisms underpinning regulation of the allogeneic immune response in humans are not known. In this study, we evaluated the distinct effects of human in vitro expanded and flow-sorted ...

journal_title：Oncoimmunology

authors： Coman T,Rossignol J,D'Aveni M,Fabiani B,Dussiot M,Rignault R,Babdor J,Bouillé M,Herbelin A,Coté F,Moura IC,Hermine O,Rubio MT

更新日期：2018-08-23 00:00:00

abstract：:In the context of a Phase I clinical trial, the long-term vaccination of advanced biliary tract cancer patients with peptides derived from four distinct cancer-testis antigens resulted in remarkable disease stability and in the elicitation of antigen-specific T-cell responses. ...

journal_title：Oncoimmunology

authors： Aruga A

更新日期：2013-07-01 00:00:00

abstract：:Despite the opposite roles of Tbet and Foxp3 in the immune system as well as in tumour biology, recent studies have demonstrated the presence of of CD4+ T cells, expressing both, Tbet and Foxp3. Although Tbet+Foxp3+ T cells are currently a subject of intense research, less is known about their biological function espe...

journal_title：Oncoimmunology

authors： Kachler K,Holzinger C,Trufa DI,Sirbu H,Finotto S

更新日期：2018-04-25 00:00:00

abstract：:Recent studies on the processes that lead to the development of pancreatic cancer indicate that inflammatory macrophages have key functions in the initiation of pre-neoplastic lesions. Specifically, acquisition of an activating Kras mutation in pancreatic acinar cells leads to upregulation of intercellular adhesion mo...

journal_title：Oncoimmunology

authors： Storz P

更新日期：2015-03-19 00:00:00

abstract：:Efforts to reduce immunosuppression in the solid tumor microenvironment by blocking the recruitment or polarization of tumor associated macrophages (TAM), or myeloid derived suppressor cells (MDSCs), have gained momentum in recent years. Expanding our knowledge of the immune cell types, cytokines, or recruitment facto...

journal_title：Oncoimmunology

authors： Moyes KW,Davis A,Hoglund V,Haberthur K,Lieberman NA,Kreuser SA,Deutsch GH,Franco S,Locke D,Carleton MO,Gilbertson DG,Simmons R,Winter C,Silber J,Gonzalez-Cuyar LF,Ellenbogen RG,Crane CA

更新日期：2018-08-27 00:00:00

abstract：:Immunomodulation is an important part of lenalidomide's mode of action. We analyzed the impact of lenalidomide on T cells from patients with multiple myeloma during lenalidomide therapy in vivo and in patients with lenalidomide-refractory disease in vitro Patients enrolled in the German Speaking Myeloma Multicenter Gr...

journal_title：Oncoimmunology

authors： Krämer I,Engelhardt M,Fichtner S,Neuber B,Medenhoff S,Bertsch U,Hillengass J,Raab MS,Hose D,Ho AD,Goldschmidt H,Hundemer M

更新日期：2016-02-18 00:00:00

abstract：:We have previously reported that direct injection of dendritic cells (DC) engineered to express the Type-1 transactivator Tbet (i.e., DC.Tbet) into murine tumors results in antitumor efficacy in association with the development of structures resembling tertiary lymphoid organs (TLO) in the tumor microenvironment (TME)...

journal_title：Oncoimmunology

authors： Weinstein AM,Chen L,Brzana EA,Patil PR,Taylor JL,Fabian KL,Wallace CT,Jones SD,Watkins SC,Lu B,Stroncek DF,Denning TL,Fu YX,Cohen PA,Storkus WJ

更新日期：2017-04-28 00:00:00

abstract：:Surgical resection of the primary tumor provides the best chance of cure for patients with colorectal carcinoma (CRC). However, bacterial translocation during intestinal surgery has been correlated with poor long-term oncological outcome. Therefore, we investigated the influence of bacterial contamination during colon...

journal_title：Oncoimmunology

authors： Grewal S,Korthouwer R,Bögels M,Braster R,Heemskerk N,Budding AE,Pouw SM,van Horssen J,Ankersmit M,Meijerink J,van den Tol P,Oosterling S,Bonjer J,Gül N,van Egmond M

更新日期：2018-07-26 00:00:00

abstract：:Checkpoint inhibition has established immunotherapy as a major modality of cancer treatment. However, the success of cancer immunotherapy is still limited as immune regulation of tumor immunity is very complicated and mechanisms involved may also differ among cancer types. Beside checkpoints, other good candidates for...

journal_title：Oncoimmunology

authors： Terabe M,Robertson FC,Clark K,De Ravin E,Bloom A,Venzon DJ,Kato S,Mirza A,Berzofsky JA

更新日期：2017-03-31 00:00:00